AVBP vs LEN · $1.39B cap vs rev $34.19B
ArriVent BioPharma, Inc. Common Stock (AVBP) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
ArriVent BioPharma, Inc. Common Stock (AVBP) is a biotechnology company listed on US.
LEN (LEN) common stock.
AVBP does not have a complete income-statement cache yet.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
AVBP currently screens at market cap $1.39B. LEN currently screens at market cap $0.
Not investment advice. Open the AVBP and LEN stock pages for the full models.
Not investment advice.